Vernalis buys back frovatriptan royalties and completes turnaround
This article was originally published in Scrip
Executive Summary
Vernalis has reached an agreement with Paul Capital Healthcare to regain the right to all the royalties from Menarini's sales of frovatriptan (25.25% of net sales).